Business Type:Lab/Research institutions
Product Certification&
Enterprise Certification
Country: China (Mainland)
Business Type:Lab/Research institutions
We are a CRO company, and our Research and Development team is consisted of PhDs and Masters in chemistry and pharmacy.
We are committed to protect our customer’s privacy with the highest level of ethical standard. Our dedicated team will follow up on every order and provide instant feedback on the status to our customer.
We stand behind our product by providing a complete QA report. The test data of customer order can be provided upon request.
We make our efforts to offer customer innovative, customized, high-quality service.
Our custom manufacturing encompasses everything from pharmaceutical intermediates to API.
AMG319 is a potent and selective PI3Kδ inhibitor with IC50 of 18 nM, also inhibits PI3Kγ with IC50 of 850 nM. IC50: 18 nM (PI3Kδ), 850 nM (PI3Kγ), 2.7μM (PI3Kβ), 33 μM (PI3Kα) Target: PI3K In vitro: AMG319 is a compound with an IC50 of 16 nM in a human whole blood assay (HWB), excellent selectivity over a large panel of protein kinases, and a high level of in vivo efficacy as measured by two rodent disease models of inflammation. AMG319 inhibits anti-IgM/CD40L-induced B cell proliferation with IC50 of 8.6 nM and reduces pAkt level with IC50 of 1.5 nM. AMG319 also inhibits anti-IgD-induce CD-69 expression in HWB.[1] In vivo: In female Lewis rats, AMG319 (3 mg/kg, p.o.) inhibits the KLH-induced inflammatory response by 88%. In the transgenic (IgMm) mice, AMG319 (, p.o.) inhibits in vivo pAKT with IC50 of 1.9 nM